Daniel was diagnosed with Guillain-Barré syndrome, a rare neurological disorder that occurs when a person's immune system ...

Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC ...

According to CDC researchers, cases of tularemia in the U.S. increased by nearly 60% from 2011 to 2022 compared with the ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® ( RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...

Scientists at the Garvan Institute of Medical Research have discovered how a viral infection causes autoimmune disease, disproving a long-standing ...

ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA SubmissionANX007 First Potential ...